Rodriguez-Adrian L, Comegna M, Guzman M, Isturiz M, Murillo J; International Conference on AIDS.

Int Conf AIDS. 1994 Aug 7-12; 10: 201 (abstract no. PB0817).

Hospital Privado Centro Medico de Caracas, Venezuela.

OBJECTIVE: Evaluate survival of patients infected with HIV (asymptomatic, ARC and AIDS) treated with Zidovudine and followed by a private practice group between 1985 and 1993. METHODS: We retrospectively reviewed 321 charts of patients infected with HIV infection. Seventy nine fulfilled the following criteria: CD4 lymphocytes less than 500 cell/ml, treatment for six months or longer, dosage equal or greater than 300 mg/day, and follow up of no less than 12 months. Median and cumulative probability of survival were calculated using Kaplan-Meier techniques. RESULTS: Overall survival of 17 asymptomatic treated patients was 100% at 68 months. For 23 patients with ARC the probability of survival was 90% at 1 year and 55% at 5 years. The median survival for 39 patients with AIDS was 31 months, and the probability of survival for the same patients was 89% at 1 year and 23% at 5 years. DISCUSSION AND CONCLUSIONS: 1. Compared to historical untreated controls, our patients survived longer and the survival was similar to that reported in the world literature, for the Zidovudine treated patients. 2. Treatment with Zidovudine appears useful for patients infected with HIV in our country. 3. The lowest effective dose of Zidovudine should be evaluated prospectively in our patient population.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• AIDS-Related Complex
• Acquired Immunodeficiency Syndrome
• CD4-Positive T-Lymphocytes
• HIV Infections
• HIV Seropositivity
• Humans
• Survival
• Survival Analysis
• Venezuela
• Zidovudine

Other ID:

• 94371444

UI: 102210277

From Meeting Abstracts